T. Rowe Price Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.4B | Sell |
4,281,279
-136,866
| -3% | -$44.6M | 0.88% | 20 |
|
|
2025
Q1 | $1.19B | Buy |
4,418,145
+33,696
| +0.8% | +$9.1M | 0.79% | 22 |
|
|
2024
Q4 | $1.03B | Buy |
4,384,449
+1,245,195
| +40% | +$293M | 0.64% | 40 |
|
|
2024
Q3 | $863M | Sell |
3,139,254
-14,373
| -0.5% | -$3.95M | 0.52% | 57 |
|
|
2024
Q2 | $766M | Buy |
3,153,627
+280,723
| +10% | +$68.2M | 0.48% | 64 |
|
|
2024
Q1 | $429M | Sell |
2,872,904
-553,159
| -16% | -$82.7M | 0.26% | 102 |
|
|
2023
Q4 | $656M | Buy |
3,426,063
+27,204
| +0.8% | +$5.21M | 0.43% | 74 |
|
|
2023
Q3 | $602M | Buy |
3,398,859
+161,235
| +5% | +$28.6M | 0.43% | 67 |
|
|
2023
Q2 | $615M | Buy |
3,237,624
+206,803
| +7% | +$39.3M | 0.42% | 68 |
|
|
2023
Q1 | $607M | Sell |
3,030,821
-171,972
| -5% | -$34.4M | 0.44% | 59 |
|
|
2022
Q4 | $761M | Buy |
3,202,793
+10,609
| +0.3% | +$2.52M | 0.58% | 44 |
|
|
2022
Q3 | $639M | Buy |
+3,192,184
| New | +$639M | 0.51% | 54 |
|